Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 29754585

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Immunother Cancer
Publication date
2018 May 14
First author
Boyiadzis MM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Boyiadzis MM
      type
      Author
    2. name
      Kirkwood JM
      type
      Author
    3. name
      Marshall JL
      type
      Author
    4. name
      Pritchard CC
      type
      Author
    5. name
      Azad NS
      type
      Author
    6. name
      Gulley JL
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Boyiadzis MM
      type
      Author
    2. name
      Kirkwood JM
      type
      Author
    3. name
      Marshall JL
      type
      Author
    4. name
      Pritchard CC
      type
      Author
    5. name
      Azad NS
      type
      Author
    6. name
      Gulley JL
      type
      Author
    bibliography ids
    1. nci-bib-82549645e613295c45b7b826
    book metadata
    content sha256
    e944e946b5603794890562508d3e39bcbed844878f72cfd3727520f2a48ce8e2
    document type
    citation
    dois
    1. 10.1186/s40425-018-0342-x
    electronic publication date
    display
    2018 May 14
    precision
    day
    year
    2018
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:29754585
    immutable id
    pubmed:29754585@e944e946b5603794890562508d3e39bcbed844878f72cfd3727520f2a48ce8e2
    journal
    abbreviation
    J Immunother Cancer
    issn electronic
    2051-1426
    issn print
    Source null
    issue
    1
    name
    Journal for immunotherapy of cancer
    nlm unique id
    101620585
    pages
    35
    volume
    6
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      29754585
      provenance
      batch id
      c4c0356d060413f719c2
      provider
      NCBI PubMed ESummary
      record sha256
      600ee88d0ececbb87f8b682885ce3bc793b33bf8b44e7d8948c12c548478a5b5
      response sha256
      adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
      retrieved at
      2026-09-09T23:47:33.674758+00:00
      publication date
      display
      2018 May 14
      precision
      day
      year
      2018
      publication types
      1. Journal Article
      2. Review
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/29754585/
      title
      Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

      Preserved source evidence · Independent clinical review pending · Not medical advice